UB 621

Drug Profile

UB 621

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator United BioPharma
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Herpes simplex virus infections

Most Recent Events

  • 01 Jan 2017 United BioPharma completes a phase I trial in Herpes simplex virus infections (In volunteers) in Taiwan (SC) (NCT02346760)
  • 01 Dec 2015 Phase-I clinical trials in Herpes simplex virus infections (In volunteers) in Taiwan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top